🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

LAST CHANCE to join us for our Post-ASH 2024 #Myeloma Highlights TOMORROW🩸 Presentations & discussions on selected abstracts from #ASH24 Unpack groundbreaking findings & join the conversation🔦 Marc Raab, Dr Yi Lin & Dr Elena Zamagni 👉ow.ly/zcS250UPlLR #MPNsm

📣 We are excited to announce the 10th Heidelberg Myeloma Workshop   Join us on April 25–26, 2025, as international & local experts share the latest advancements in multiple myeloma research. #mmsm ✅ CME-certified 🔗 Speaker line-up & registration 👇🏼 myelomaworkshop.de

Attend on-site or virtually! Confirmed speakers include IdoAmitLab nizar jacques bahlis Francesco Maura Bruno Paiva Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Shaji Kumar Martin Kaiser Sagar Lonial MD Tom Cupedo Leif Bergsagel Gareth Morgan Mark Bustoros and many more!!

So proud of our team Heidelberg Myeloma !

New publication 📝 Phase II results from MajesTEC-5 show promising early efficacy and MRD negativity for Tec-DR and Tec-DVR for TE-NDMM. Learn more: loom.ly/RiJFyP0 #myeloma #mmsm #MultipleMyeloma #MedNews #MedEd

What a great collaborative effort! Kudos to Martin Kaiser, Niels Weinhold Heidelberg Myeloma, and many others around the globe for putting this together

Very happy to see our global collaborative effort published in Journal of Clinical Oncology : co-occurrence of ≥2 HRCAs is consistently associated with highest unmet need in NDMM and RRMM, across time and treatment modalities. ascopubs.org/doi/10.1200/JC…

Register for our #Myeloma #MRD meeting to hear from Marc S. Raab on GMMG-HD7 and PERSEUS Trials🩸💻 👉 us06web.zoom.us/webinar/regist… 🗓️ 11 April 📍Online #MultipleMyeloma #MMsm HealthTree Foundation Sylvester Comprehensive Cancer Center Multiple Myeloma RF International Myeloma Foundation

We just heard from Holly Lee (U Calgary) at #iwGPRC5D2025, who gave a fascinating presentation on clonal evolution and its impact on GPRC5D antigen expression. #MMsm #HemOnc

Even with increasingly intensive therapy regimens, high-risk patients perform worse. There is a high demand for precision diagnostics to determine the individual benefit. Martin Kaiser gave a talk on the aspects to take into account at this year's #ESHMM2025 #ESHCONFERENCES #MMsm

With novel insights into the biology of MM, precision medicine could be the answer to some of our burning questions. Which drug to choose based on genomics? 🧬 Marc Raab presented some previously investigated agents and hinted at future options. #ESHMM2025 #ESHCONFERENCES #MMsm

Another great presentation here at #MyelomaMRD2025! We just heard from Marc S. Raab, who shared updates from the GMMG-HD7 & PERSEUS trials. So much to learn regarding MRD in myeloma today🩸 #MMsm #mmMRD Sylvester Comprehensive Cancer Center C. Ola Landgren, M.D. Multiple Myeloma RF HealthTree Foundation

Truly excellent keynote lecture from Leo Rasche on the bone marrow ecosystem and the evolution to MM chaired by Niels Weinhold

🧵A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma 1/Real-World Effectiveness of Talquetamab: - In 123 evaluable patients, the overall response rate was 65%, with 26% achieving a nCR or better. - PFS was 6.4 months

The optimal management of relapsed and/or refractory multiple myeloma in patients who have previously received frontline high-dose chemotherapy and autologous stem cell transplantation remains a subject of ongoing debate. ow.ly/W5iT50VCOEc #clinicaltrialsandobservations

#Myeloma Paper of the Day: Elotuzumab w/ IMiDs and dex for relapsed/refractory AL #amyloidosis shows hematologic response by 3 months in 32%; 4/33 had organ responses; median OS was 37 months and EFS was 11 months: pubmed.ncbi.nlm.nih.gov/40276975/. #mmsm

Spontaneous farewell dinner, wrapping-up the Workshop Thank you all for making this event such a great success!

Researchers, including Drs. Jan Frenking and Marc S. Raab from Universitätsklinikum Heidelberg, highlight that bridging intensity distinctly shapes the trajectory of #hematopoietic recovery after B-cell maturation antigen CAR-T. 📚 More in Blood Advances: bit.ly/4jT2Kvu

7500 – MIDAS Trial: MRD-Guided Therapy Post-IsaKRd 718 NDMM pts. After Isa-KRd x6, 67% were MRD− at 10⁻⁵. Randomized to continue Isa-KRd x 6 or go to ASCT prior to maintenance. No difference in MRD<10⁻6 (84% vs 86%) thus far! And as for MRD(+) post-induction: no difference

How to better end sizzling hot days at #EHA2025 than by enjoying delicious food with close friends nizar jacques bahlis, Martin Kaiser, Paola Neri